Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Inclusion Criteria: * Unresectable or treatment-resistant patients with Hepatocellular carcinoma * Measurable disease by CT scan * ECOG performance status 0-2 * Life expectancy \> 3 months * Laboratory values as follows: 2,000/mm3 \< WBC \<15,000/mm3, Platelet counts \> 75,000/mm3, Total Bilirubin \< 1.5 mg/dl, Asparate transaminase \< 150IU/L, Alanine transaminase \< 150 IU/L, Creatinine \< 3.0mg/dl * HLA-A\*2402 * Able and willing to give valid written informed consent Exclusion Criteria: * Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception) * Brest-feeder * Active or uncontrolled infection * Steroids or immunosuppressing agent dependent status * Active or uncontrolled other malignancy * Serious or uncured wound * Decision of unsuitableness by principal investigator or physician-in charge